YolTech Therapeutics has closed a Series B financing round of approximately forty-five million dollars, led by the AstraZeneca-CICC healthcare investment fund. The new funding will advance the company’s efforts to move its clinical programs forward and support its plans for global development and commercialization.
Since its founding in 2021, YolTech has built a fully integrated gene-editing platform designed to deliver one-time therapies directly inside the body. The company’s core technologies include its own CRISPR-based nucleases, precision base editors, and a specialized lipid nanoparticle delivery system. Combined, these tools enable precise editing of disease-causing genes in specific tissues without the need for repeated treatments.
YolTech’s lead therapy candidate, YOLT-201 for transthyretin amyloidosis, became the first in-body gene-editing treatment to enter a Phase I/IIa clinical trial in China. In parallel, the company has advanced three additional programs into clinical testing for familial hypercholesterolemia, primary hyperoxaluria type 1, and blood disorders such as beta-thalassemia and sickle cell disease. These programs reflect YolTech’s ambition to tackle a diverse set of inherited conditions that currently have limited treatment options.
To ensure consistent supply and scale-up, YolTech operates a cGMP-compliant manufacturing facility capable of producing clinical-grade material through Phase III and supporting early commercial demand. This in-house production capability gives the company tight control over quality and timelines as its therapies progress through regulatory milestones.
YolTech has also made history with its base-editing therapy YOLT-101 for familial hypercholesterolemia, which achieved investigational new drug clearance in both China and the United States. This dual-country approval underscores the strength of the company’s scientific approach and its readiness to bridge multiple regulatory environments.
With one of the most advanced in-body gene-editing pipelines in the world, YolTech is positioning itself as a leader in the effort to turn laboratory breakthroughs into lasting treatments. The latest financing round will accelerate the company’s clinical trials, expand its global footprint, and bring innovative gene-editing medicines closer to patients in need.
KEY QUOTES:
“This financing marks an important milestone as we continue advancing our pipeline toward transformative therapies. We are committed to turning cutting-edge gene-editing science into real-world treatments for patients worldwide.”
Dr. Yuxuan Wu, Founder and CEO of YolTech
